Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics
- Glaxo proposes ‘biopreparedness’ facility to develop vaccines
- Japan, Norway, Gates among financial contributors to coalition
Glaxo CEO Seeks Greater Transparency on Drug Pricing
This article is for subscribers only.
Spurred by the Ebola and Zika epidemics, GlaxoSmithKline Plc, Johnson & Johnson and Sanofi are among drugmakers backing an effort to develop new vaccines that could be deployed swiftly to contain outbreaks before they spark global emergencies.
Pharmaceutical companies are working with the Coalition for Epidemic Preparedness Innovations, which has raised $460 million from the governments of Germany, Japan and Norway, as well as the Bill & Melinda Gates Foundation and the Wellcome Trust, the group said on Wednesday.